source
- Yarrow Bioscience raises $150M as AbbVie reports positive menstrual migraine trial resultsYarrow Bioscience, based in New Haven, announced pricing of a $150 million equity offering at $26 per share, roughly $2.50 below the previous closing price. The capital raise will provide addition…
- Trade group warns stalled biosimilar development could forfeit billions in savingsA trade association that represents generic drug makers and biosimilar developers released a new report warning that progress on biosimilar products has slowed. The group says the slowdown threaten…